Literature DB >> 32042625

A novel biparametric magnetic resonance imaging sequence provides a more efficient and similarly efficacious method of risk stratifying men clinically suspected of having prostate cancer.

Megan Stout1, Tasha Posid1, Shawn Dason1.   

Abstract

Entities:  

Year:  2019        PMID： 32042625      PMCID： PMC6989853          DOI： 10.21037/tau.2019.09.35

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  6 in total

1.  Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.

Authors:  Marloes van der Leest; Erik Cornel; Bas Israël; Rianne Hendriks; Anwar R Padhani; Martijn Hoogenboom; Patrik Zamecnik; Dirk Bakker; Anglita Yanti Setiasti; Jeroen Veltman; Huib van den Hout; Hans van der Lelij; Inge van Oort; Sjoerd Klaver; Frans Debruyne; Michiel Sedelaar; Gerjon Hannink; Maroeska Rovers; Christina Hulsbergen-van de Kaa; Jelle O Barentsz
Journal:  Eur Urol       Date:  2018-11-23       Impact factor: 20.096

2.  Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.

Authors:  Olivier Rouvière; Philippe Puech; Raphaële Renard-Penna; Michel Claudon; Catherine Roy; Florence Mège-Lechevallier; Myriam Decaussin-Petrucci; Marine Dubreuil-Chambardel; Laurent Magaud; Laurent Remontet; Alain Ruffion; Marc Colombel; Sébastien Crouzet; Anne-Marie Schott; Laurent Lemaitre; Muriel Rabilloud; Nicolas Grenier
Journal:  Lancet Oncol       Date:  2018-11-21       Impact factor: 41.316

Review 3.  Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.

Authors:  Baris Turkbey; Andrew B Rosenkrantz; Masoom A Haider; Anwar R Padhani; Geert Villeirs; Katarzyna J Macura; Clare M Tempany; Peter L Choyke; Francois Cornud; Daniel J Margolis; Harriet C Thoeny; Sadhna Verma; Jelle Barentsz; Jeffrey C Weinreb
Journal:  Eur Urol       Date:  2019-03-18       Impact factor: 20.096

4.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

5.  Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.

Authors:  Ivan Jambor; Janne Verho; Otto Ettala; Juha Knaapila; Pekka Taimen; Kari T Syvänen; Aida Kiviniemi; Esa Kähkönen; Ileana Montoya Perez; Marjo Seppänen; Antti Rannikko; Outi Oksanen; Jarno Riikonen; Sanna Mari Vimpeli; Tommi Kauko; Harri Merisaari; Markku Kallajoki; Tuomas Mirtti; Tarja Lamminen; Jani Saunavaara; Hannu J Aronen; Peter J Boström
Journal:  PLoS Med       Date:  2019-06-03       Impact factor: 11.069

6.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.